Company Encyclopedia
View More
name
Hicin Pharmaceutical
300584.SZ
Nanjing Hicin Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of chemical preparations, APIs, and intermediates. The company’s products include landiolol hydrochloride, rivaroxaban, tigecycline, torasemide, cefotiam hydrochloride, and adenosine monophosphate for injection; voglibose tablets, ansoprazole enteric-coated tablets, amlodipine besylate tablets, and glucosamine sulfate effervescent tablets/granules; and raw materials, intermediates, and other products. Its products are used in cardiovascular and cerebrovascular, diuretic, anti-infection, digestive system, immune regulation, hypoglycemic, orthopedics, and other treatment areas. Nanjing Hicin Pharmaceutical Co., Ltd.
3.159 T
300584.SZMarket value -Rank by Market Cap -/-

Financial Score

06/12/2025 Update
B
PharmaceuticalsIndustry
Industry Ranking51/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE4.36%C
    • Profit Margin7.28%B
    • Gross Margin84.38%A
  • Growth ScoreB
    • Revenue YoY22.98%A
    • Net Profit YoY6.59%C
    • Total Assets YoY4.24%C
    • Net Assets YoY6.25%B
  • Cash ScoreB
    • Cash Flow Margin1374.26%B
    • OCF YoY22.98%A
  • Operating ScoreC
    • Turnover0.42C
  • Debt ScoreB
    • Gearing Ratio27.65%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    The solid-state battery concept fluctuates and strengthens, GMK rises over 15%

    In the morning session, the solid-state battery concept fluctuated and strengthened, with GMK rising over 15%. Previously, DFD hit the daily limit, and Hicin Pharmaceutical, zhenhua chemical, Ongo, Cangzhou Mingzhu, and Haike Xinyuan also followed suit

    Zhitong·
    SH
    603067
    +10.00%
    SZ
    002108
    -1.43%
    SZ
    300619
    -1.49%
    Zhitong·
    SH
    603067
    +10.00%
    SZ
    002108
    -1.43%
    SZ
    300619
    -1.49%

    On October 27th, Hicin Pharmaceutical stated on the interactive platform that the company's lithium sulfide project has completed the pilot line construction as planned and is orderly advancing the trial production work

    Zhitong·
    SZ
    300584
    +0.43%
    Zhitong·
    SZ
    300584
    +0.43%

    Hicin Pharmaceutical released its performance for the first three quarters, with a net profit attributable to the parent company of 32.6785 million yuan, a year-on-year increase of 16.22%

    According to the Zhitong Finance APP, Hicin Pharmaceutical released its third-quarter report for 2025. In the first three quarters, the company achieved operating revenue of 472 million yuan, a year-on-year increase of 30.80%. The net profit attributable to shareholders of the listed company was 32.6785 million yuan, a year-on-year increase of 16.22%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 29.5431 million yuan, a year-on-year increase of 1.64%

    Zhitong·
    SZ
    300584
    +0.43%
    Zhitong·
    SZ
    300584
    +0.43%

    Hicin Pharmaceutical: The net profit attributable to the parent company in the third quarter was 3.5208 million yuan, a year-on-year increase of 4.15%

    On October 22nd, Hicin Pharmaceutical announced that the company achieved operating revenue of 163 million yuan in the third quarter of 2025, a year-on-year increase of 31.45%; the net profit attributable to shareholders of the listed company was 3.5208 million yuan, a year-on-year increase of 4.15%. In the first three quarters, the company achieved operating revenue of 472 million yuan, a year-on-year increase of 30.80%; the net profit attributable to shareholders of the listed company was 32.6785 million yuan, a year-on-year increase of 16.22%

    Zhitong·
    SZ
    300584
    +0.43%
    Zhitong·
    SZ
    300584
    +0.43%

    Hicin Pharmaceutical: Will send representatives to attend the Hefei Solid-State Battery Conference in October

    On September 17th, Hicin Pharmaceutical stated on the interactive platform that the company will send representatives to attend the solid-state battery conference in Hefei in October

    Zhitong·
    SZ
    300584
    +0.43%
    Zhitong·
    SZ
    300584
    +0.43%
    © 2025 Longbridge｜Disclaimer